What Are the Risks of HRT? What the Evidence Actually Shows

No menopause treatment carries more fear than hormone replacement therapy - and no menopause treatment has a bigger gap between the headlines and the evidence. Some of HRT's risks are real and worth taking seriously. Others are echoes of a 2002 study that was misread at the time and has been substantially reinterpreted since.

Here is what the evidence actually shows, risk by risk, in absolute numbers - because "doubles the risk" means very little until you know the starting number.

First, the history that created the fear

In 2002, the Women's Health Initiative (WHI) - a huge randomized trial - was stopped early after finding increased breast cancer, heart disease, stroke, and clot risk with combined HRT. Prescriptions collapsed worldwide almost overnight.

What got lost: the average WHI participant was 63 years old - more than a decade past menopause - and took an older oral formulation. Twenty years of follow-up and reanalysis have shown the picture is very different for the women who actually take HRT today: those in their late 40s and 50s, close to menopause, often using skin-delivered estrogen. Long-term WHI follow-up found no increase in overall mortality from HRT use. The 2026 FDA labeling update reflects this more accurate, timing-aware view.

That does not make HRT risk-free. It means the risks are specific, mostly small, and manageable - and they deserve precise description.

Breast cancer: the most feared risk

• Combined HRT (estrogen plus progestogen - what you take if you have a uterus) is associated with a small increase in breast cancer risk after several years: in the WHI, roughly one extra case per 1,000 women per year of use, and the risk declines after stopping.
• Estrogen-only HRT (after hysterectomy) showed no increase in the WHI - if anything, a slight reduction in breast cancer deaths over long follow-up.
• The type of progestogen matters: observational evidence suggests body-identical micronized progesterone carries a lower breast cancer risk than older synthetic progestogens.

For perspective: the added risk from combined HRT is of similar size to the risk associated with drinking two units of alcohol a day or being significantly overweight - real, but rarely described with the same alarm.

What lowers it: using micronized progesterone, keeping duration under periodic review, and routine mammograms on schedule.

Blood clots: the risk that depends on delivery

Oral estrogen passes through the liver first, where it increases clotting factors:

• Tablets roughly double the risk of venous thromboembolism (DVT and pulmonary embolism). In absolute terms: from about 1-2 per 1,000 women per year to about 2-4.
• Patches, gels, and sprays bypass the liver, and the evidence shows little to no added clot risk with transdermal estrogen - which is why it is now the default recommendation, especially for women with any clot risk factor, including a raised BMI.

What lowers it: choosing transdermal delivery. For most women that single choice removes the bulk of this risk.

Stroke: small, and again delivery-dependent

Oral HRT is associated with a small increase in ischemic stroke risk - in younger menopausal women the baseline risk is low, so the absolute increase is small (roughly one extra stroke per 1,000 women over five years in their 50s). Transdermal estrogen at standard doses has not shown this increase in observational studies.

Heart disease: it is about timing, not just the hormone

This is where the story reversed most dramatically. The current evidence supports a "timing hypothesis":

• Started within 10 years of menopause and before age 60, HRT does not increase coronary heart disease - and some analyses suggest a modest protective trend.
• Started more than 10-20 years after menopause, when arteries may already have plaque, oral HRT can increase cardiac events.

This is why every modern guideline anchors the benefit-risk balance to the window in which you start - and why HRT is not recommended purely for heart protection either.

Other risks worth knowing

• Gallbladder disease: oral estrogen modestly raises the risk of gallstones; transdermal appears safer here too.
• Endometrial cancer: only a risk if estrogen is taken without progesterone by a woman with a uterus - which is exactly why combined HRT exists.
• Ovarian cancer: meta-analyses suggest a very small possible increase (well under one extra case per 1,000 users over five years); the evidence is observational and debated.
• Dementia: starting oral HRT late (65+) was linked to increased dementia risk in the WHI Memory Study; started near menopause, current evidence shows no clear increase - another timing effect.

The risks vaginal estrogen does NOT carry

Local vaginal estrogen - creams, pessaries, tablets, and rings for dryness and urinary symptoms - delivers a tiny dose with minimal absorption into the bloodstream. Guidelines are consistent: it does not carry the breast cancer, clot, or stroke risks of systemic HRT, does not require progesterone, and can be used long-term at any age, including by many women advised against systemic HRT. Fear of "hormones" stops many women using the one form that is nearly risk-free.

Who should not take systemic HRT

HRT is generally avoided or needs specialist input if you have:

• Current, past, or suspected breast cancer, or certain other hormone-sensitive cancers
• Unexplained vaginal bleeding (investigate first - always)
• A history of blood clots or stroke (transdermal may still be possible with specialist advice)
• Active liver disease
• Untreated high blood pressure (treat it first)
• Pregnancy - not as rare a scenario in perimenopause as assumed

A strong family history of breast cancer or a BRCA mutation does not automatically rule HRT out, but it moves the conversation to a specialist.

How to think about it - and lower your own risk

1. Anchor on absolute numbers. "One extra case per 1,000 per year" and "doubles the risk" can describe the same fact; only the first tells you its size.
2. Start in the window - under 60 or within 10 years of menopause - where the balance is most favorable.
3. Prefer transdermal estrogen and micronized progesterone - the two formulation choices that trim the clot, stroke, and possibly breast cancer risks.
4. Review annually. The balance is personal and shifts with age and health changes - a standing reappointment, not a one-time verdict.
5. Use vaginal estrogen freely if dryness and urinary symptoms are the main problem - it is the low-risk tool built for exactly that job.

How Femora helps

A risk conversation works best with a clear picture of what HRT is actually doing for you - because the benefit side of the scale is personal too. Logging your symptoms with the menopause symptom score before and after starting shows exactly how much relief treatment provides, which is half of every annual review. If you are just starting, our guide to what to expect when you start HRT covers the first months, and the full HRT guide covers the benefit side of this ledger in the same detail.

The bigger picture

The honest summary of two decades of evidence: for most healthy women who start near menopause, HRT's benefits outweigh its risks, and the risks that remain are small in absolute terms and further reducible by formulation choices. For women outside that window, or with specific histories, the balance genuinely shifts - which is why the right answer is not "HRT is safe" or "HRT is dangerous" but a yearly, personal calculation made with real numbers.

This is general information, not a substitute for advice from your own clinician. Download Femora to bring real symptom data to that conversation.